Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0424 Transporter Info
Gene Name SLC5A4
Transporter Name Sodium/glucose cotransporter 3
Gene ID
6527
UniProt ID
Q9NY91
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Drug in Phase 3 Trial

  SaxaDapa FDC

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 SaxaDapa FDC modulates the activity of SLC5A4 [3] , [4]

  RG7201

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 RG7201 modulates the activity of SLC5A4 [6]

Drug in Phase 2 Trial

  Remogliflozin etabonate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Remogliflozin etabonate blocks the activity of SLC5A4 [5]

  Remogli ozin-etabonate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Remogli ozin-etabonate modulates the activity of SLC5A4 [7]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene increases the expression of SLC5A4 [1]

Health and Environmental Toxicant

  Diethylhexyl Phthalate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diethylhexyl Phthalate inhibits the expression of SLC5A4 [2]
References
1 Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
2 Di-(2-ethylhexyl)-phthalate induces apoptosis via the PPAR Gamma/PTEN/AKT pathway in differentiated human embryonic stem cells. Food Chem Toxicol. 2019 Sep;131:110552.
3 Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
4 The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
7 Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.